MCB Q2 Earnings Slump: Net Income Halves Sequentially, Undermining Momentum Thesis

What happened

MCB reported Q2 2026 net income of $19.2 million ($1.54 per share), down 39% from Q1's $31.4 million ($2.92 per share) and only marginally above the $18.8 million ($1.76 per share) in Q2 2025. The sequential decline is sharper than anticipated, especially given that Q1 results were inflated by a $0.42 per share reserve methodology benefit that did not recur. Loan growth and net interest margin likely faced pressure as the pipeline conversion proceeds, while funding costs or credit costs may have normalized upward. The deep concentration in CRE/SNF (85.9% and 38.8% of loans, respectively) remains a critical vulnerability, and Q2's earnings suggest the momentum narrative is losing steam. At ~$93, the stock prices in the continuation of outperformance that Q2 has already contradicted.

Implication

Q2 2026 earnings of $1.54 per share are well below the Q1 implied run-rate, confirming that Q1 was artificially inflated by a reserve adjustment. The stock's premium valuation lacks support given elevated CRE/SNF concentration and rising risk of funding pressure. Investors should avoid adding positions until the stock pulls back toward the $85 attractive entry point and there is evidence of sustainable earnings power.

Thesis delta

Q2 results represent a significant step-down from Q1, reversing the momentum that had driven the stock to $93. The narrative of sustained strong earnings is now contradicted, as the reserve benefit is gone and core earnings appear lower. The WAIT rating is validated; a reassessment of the attractive entry price may be warranted if Q2 trends continue.